BIND Biosciences Co-Founder Selected as 2009 Mass High Tech All-Star
CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing an entirely new class of targeted nanotherapeutics, announced today the selection of Omid Farokhzad, M.D., co-Founder and member of the Board of Directors and Scientific Advisory Board, as a 2009 Mass High Tech All-Star for his contributions in life sciences. In addition, Dr. Farokhzad is an Associate Professor at Harvard Medical School and Physician-Scientist at Brigham and Women’s Hospital. Now in its fourteenth year, the annual All-Star awards program recognizes dynamic and influential leaders across several business and technology sectors in New England’s innovation economy. This year’s honorees will be honored this evening at an awards ceremony at the Park Plaza Hotel in Boston.
“This award is a testament to the efforts and achievements of BIND in translating academic research and innovation into the development of important treatments for patients.”
“I am honored to be a 2009 Mass High Tech All-Star and receive an award from the premier journal of New England technology,” said Dr. Farokhzad. “This award is a testament to the efforts and achievements of BIND in translating academic research and innovation into the development of important treatments for patients.”
About BIND Biosciences, Inc.
BIND Biosciences is a biopharmaceutical company focused on developing targeted nanotherapeutics based upon their platform technology of self-assembling nanoparticles capable of differential delivery and controlled drug release. The company’s technology enables highly selective targeting at the cellular level and is capable of delivering bioactive agents ranging from approved drugs to emerging drug modalities. The company’s product platform is broadly applicable across the therapeutic areas of oncology, inflammatory disease, cardiovascular disease and infectious disease. Initial product development efforts are focused on cancer and inflammatory disease with their first product anticipated to enter the clinic in 2010.
BIND was founded in 2006 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer, MIT Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Associate Professor. The company licensed a large patent estate on a worldwide exclusive basis from MIT and Brigham and Women’s Hospital/Harvard Medical School covering the scientific founders’ work in targeted nanoparticle therapeutics. BIND is backed by leading venture capital firms, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners and NanoDimension. For more information, please visit the company’s web site at www.bindbio.com.